	· · · · · · · · · · · · · · · · · · ·	
	Application No.	Applicant(s)
Notice of Allowability	10/637,099	ROMINE ET AL.
	Examiner	Art Unit
	Yong Chu	1626
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to <u>12/12/2005</u> .		
2. The allowed claim(s) is/are <u>1-19</u> .		
 3. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ☐ All b) ☐ Some* c) ☐ None of the: 1. ☐ Certified copies of the priority documents have been received. 		
2. Certified copies of the priority documents have been received in Application No		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) 🔲 hereto or 2) 🔲 to Paper No./Mail Date		
(b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s)	5 □ Notice of Informal F	Patent Application (PTO 152)
1. Notice of References Cited (PTO-892)		Patent Application (PTO-152)
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. ⊠ Interview Summary Paper No./Mail Da	
3. Information Disclosure Statements (PTO-1449 or PTO/SB/0		ment/Comment
Paper No./Mail Date 10/28/2005 4. Examiner's Comment Regarding Requirement for Deposit	8. 🛛 Examiner's Stateme	ent of Reasons for Allowance
of Biological Material	9.	

Page 2

Application/Control Number: 10/637,099

Art Unit: 1626

DETAILED ACTION

Claims 1-38 are pending in the instant application. Claims 20-38 have been canceled by the Examiner's amendment.

Examiner's amendment

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Pamela A. Mingo on 26 January 2006. The application has been amended as follows:

Delete claims 20-38.

In claim 8, line 23, delete "and" after figure , and insert --,--.

In claim 8, line 23, insert --; and--.

In claim 10, line 3, delete "." after heterocycle, and insert --; --.

In claim 10, line 3, delete "." after the word heterocycle, and insert --,--.

Art Unit: 1626

Reasons for Allowance

The present invention is directed to a compound or a pharmaceutical composition for treating hepatitis C virus infection. The closest prior art of record is WO2001/JP9790 (Kontani et al.), which discloses a compound as anti-herpes agent

with structure of

. The compounds are not related to the compounds disclosed in the instant application. Applicants' co-pending application US2005/0069522A1 filed on 8/8/2003 discloses the inventions of combination pharmaceutical agents inhibitors of HCV replication. Provisional Obvious Double Patenting over some of the claims between these two applications is found. For this reason, the Examiner suggests to delete the claims 20-26. Claims 27-38 are deleted due to not enablement under 35USC112 and not statutory under 35USC101. Therefore, claims 1-19 are allowed.

Telephone Inquiry

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Yong Chu whose telephone number is 571-272-5759. The examiner can normally be reached on 7:00 am - 3:30 pm EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph McKane can be reached on 571-272-0699. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/637,099

Art Unit: 1626

Page 4

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Yong Chu, Ph.D. **Patent Examiner**

Art Unit 1626

KAMAL A. SAEED, PH.D. PRIMARY EXAMINER

Joseph M. McKane

Supervisory Patent Examiner

Art Unit 1626